Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on therapies for allergic and immunologic diseases, has announced positive initial results from its ALPHA-SOLAR long-term open-label trial. The trial evaluates navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema $(HAE)$ patients. The results showed a 95% mean monthly attack-rate reduction in the Q3M arm and an 86% reduction in the Q6M arm, demonstrating the drug's favorable safety profile. These findings were presented at the European Academy of Allergy and Clinical Immunology Annual Congress on June 13, 2025. Astria has also initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is currently enrolling patients to further evaluate navenibart's efficacy and safety.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。